Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
about
Molecular determinants of blood-brain barrier permeationMolecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsA human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate siteLysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitroPlate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound filesPrediction of the permeability of neutral drugs inferred from their solvation propertiesSmall molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.Antifungal drug discovery: the process and outcomes.Improving physical properties via C-H oxidation: chemical and enzymatic approachesA chemogenomic analysis of ionization constants--implications for drug discoveryFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Protocols utilizing constant pH molecular dynamics to compute pH-dependent binding free energiesMetabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Installing amino acids and peptides on N-heterocycles under visible-light assistance.Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteasesPotent inhibition of norovirus by dipeptidyl α-hydroxyphosphonate transition state mimics.Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies.Targeting nuclear receptors with marine natural products.Thermodynamic studies for drug design and screening.Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications.The significance of acid/base properties in drug discoveryMolecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.Strategies for a comprehensive understanding of metabolism by aldehyde oxidase.Glucocerebrosidase inhibitors for the treatment of Gaucher disease.What does the aromatic ring number mean for drug design?Novel tactics for designing water-soluble molecules in drug discovery.Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.The acid/base profile of agrochemicals.Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitorsA systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015.Network pharmacology study on the mechanism of traditional Chinese medicine for upper respiratory tract infection.Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate.N-Heterocyclic Carbene Ligand-Enabled C(sp(3))-H Arylation of Piperidine and Tetrahydropyran Derivatives.The Acid/Base Profile of the Human Metabolome and Natural Products.
P2860
Q26797482-15F482AE-0015-46BD-8648-6714AB4A56C2Q27673353-2D3D16F4-CA6F-4C8E-8B6F-DAC7FD40F18BQ27694705-CAB2C67D-F6BB-4079-B14C-C270BF8D3172Q28484924-F056087E-4D37-40C8-A7EC-0950E416D3F3Q28822337-06A69B08-4624-4BE1-9AB4-7F557018F689Q29048210-F5FD628E-E035-4815-99EF-5F1E44ABF94CQ30664269-16593E91-8FA6-47EB-9ECE-3D0E8A3416C8Q34086897-DDD02584-38A9-41B1-AC29-B98A3829A54DQ34481658-481424A0-C3E2-45F0-A0B4-1AF8163D7AC6Q34543267-A3E227E8-E92D-44A8-8CBA-AEA043563A75Q34646772-73574638-D391-4210-AF71-8D846A6EFF06Q35013427-5293BF6F-36D8-45A7-AE8F-96F55BEA4FA0Q35166429-F16FD138-C550-45DD-AE9E-0F13BAEFA148Q35348485-F9D4BB86-BA3F-48BD-92D5-03705610FBD8Q35756877-8F3DAF0D-DBB5-4BB2-9882-CAE47744FBA8Q35981110-C230CF64-E66F-4F55-B0AF-B907CB37F4C9Q36342657-1665EA78-FA94-46D8-93FC-888DF2A92E47Q36528432-9D8F23FD-5B3B-4694-8C9A-F2A16C27B62DQ36585005-99570903-040B-4BAF-AFFA-4B67BDD4F9B3Q37028683-4423592A-12F9-4B0D-8F56-8FF592FF6E75Q37114506-081733A7-CF8E-4DB1-9268-06D4B39D81E6Q37535669-093032FC-36D8-4456-B685-3AE62CFDE186Q37621100-C1D2ED0A-C567-42FA-A01E-64FB8105329BQ37998087-5CA05F8C-8F4C-4A36-BFC5-E94A9BD91AFEQ38012166-C781770F-46B3-49A6-A460-C34F82C7D20FQ38055676-CEDEF533-622A-4D38-B288-D8A07328FD1FQ38066121-B10BFC94-2A1E-4038-8E7B-30F83AF499B4Q38066611-B180BD72-D7DB-4369-BEFE-24A376258600Q38097869-2755387B-8154-48AE-8BEA-5CA07C82D6DEQ38222473-2B3A3A60-1449-4368-BB77-BBB609FB025FQ38250126-ADC8D9EF-FC10-4080-8824-EC1DF605B923Q38434145-01C5EB39-4AB5-42B7-A069-174EF6CF4705Q38643852-D5B23BEC-CA66-4B46-AD5C-85F1E8EF8BF0Q38644956-CDA3C202-B0A7-442D-8431-D850D136AA28Q38732067-73173DC5-AF73-4A6E-A49E-B8330ABE96EEQ38763312-6EC6C887-2C1C-4A73-ADCB-3BE5A1DDF50EQ38977512-EA82E949-F115-4966-82A3-7826520E2CD9Q39043724-E8F970F4-51E6-4268-8EB9-52C1391B2D33Q39424145-7AE481F4-6ED0-4DF7-A397-DB18BB408D7FQ39535327-09B397EB-9DCB-4BDB-9F2D-032709639AC9
P2860
Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Improving drug candidates by d ...... mpound disposition and safety.
@en
Improving drug candidates by d ...... mpound disposition and safety.
@nl
type
label
Improving drug candidates by d ...... mpound disposition and safety.
@en
Improving drug candidates by d ...... mpound disposition and safety.
@nl
prefLabel
Improving drug candidates by d ...... mpound disposition and safety.
@en
Improving drug candidates by d ...... mpound disposition and safety.
@nl
P356
P1476
Improving drug candidates by d ...... mpound disposition and safety.
@en
P2093
Nicholas A Meanwell
P304
P356
10.1021/TX200211V
P577
2011-07-26T00:00:00Z